Analysts at Redburn Partners started coverage on shares of Gilead Sciences, Inc. (NASDAQ:GILD) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating on the biopharmaceutical company’s stock.

GILD has been the topic of a number of other reports. BidaskClub raised Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday. Robert W. Baird reissued an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Tuesday. Leerink Swann reissued a “hold” rating and set a $74.00 target price on shares of Gilead Sciences in a report on Tuesday. BMO Capital Markets reissued a “hold” rating and set a $72.00 target price on shares of Gilead Sciences in a report on Friday, July 21st. Finally, Vetr raised Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $83.66 target price on the stock in a report on Monday, June 26th. Fifteen investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $80.09.

Shares of Gilead Sciences (GILD) traded up 0.61% during midday trading on Wednesday, reaching $74.19. The company’s stock had a trading volume of 10,683,066 shares. The company has a 50-day moving average price of $68.84 and a 200-day moving average price of $68.56. The firm has a market cap of $96.95 billion, a price-to-earnings ratio of 7.84 and a beta of 1.21. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $84.15.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.18 by $0.02. The firm had revenue of $6.51 billion for the quarter, compared to analyst estimates of $6.66 billion. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. Equities analysts expect that Gilead Sciences will post $8.42 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another publication, it was stolen and republished in violation of United States & international copyright & trademark laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/07/26/redburn-partners-begins-coverage-on-gilead-sciences-inc-gild.html.

In other Gilead Sciences news, Director John Francis Cogan sold 9,943 shares of the company’s stock in a transaction dated Tuesday, May 9th. The stock was sold at an average price of $67.25, for a total value of $668,666.75. Following the completion of the transaction, the director now owns 47,562 shares of the company’s stock, valued at approximately $3,198,544.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Gregg H. Alton sold 40,000 shares of the company’s stock in a transaction dated Friday, July 21st. The stock was sold at an average price of $74.00, for a total value of $2,960,000.00. Following the completion of the transaction, the executive vice president now directly owns 137,488 shares of the company’s stock, valued at approximately $10,174,112. The disclosure for this sale can be found here. In the last ninety days, insiders sold 128,276 shares of company stock valued at $9,190,610. Insiders own 1.30% of the company’s stock.

Large investors have recently modified their holdings of the stock. Rockland Trust Co. boosted its stake in shares of Gilead Sciences by 16.7% in the first quarter. Rockland Trust Co. now owns 178,245 shares of the biopharmaceutical company’s stock valued at $12,106,000 after buying an additional 25,551 shares during the last quarter. Linscomb & Williams Inc. boosted its stake in shares of Gilead Sciences by 3.0% in the first quarter. Linscomb & Williams Inc. now owns 5,275 shares of the biopharmaceutical company’s stock valued at $358,000 after buying an additional 154 shares during the last quarter. Berkshire Asset Management LLC PA bought a new stake in shares of Gilead Sciences during the first quarter valued at $270,000. Sigma Planning Corp boosted its stake in shares of Gilead Sciences by 7.7% in the first quarter. Sigma Planning Corp now owns 40,168 shares of the biopharmaceutical company’s stock valued at $2,728,000 after buying an additional 2,889 shares during the last quarter. Finally, Hollencrest Securities LLC boosted its stake in shares of Gilead Sciences by 119.8% in the first quarter. Hollencrest Securities LLC now owns 7,723 shares of the biopharmaceutical company’s stock valued at $525,000 after buying an additional 4,210 shares during the last quarter. 74.05% of the stock is owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.